NPCE - NeuroPace outlines 20%+ CAGR through 2027 as RNS business momentum accelerates
2025-05-13 22:34:17 ET
More on NeuroPace
- NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript
- NeuroPace, Inc. 2025 Q1 - Results - Earnings Call Presentation
- NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
- NeuroPace expects minimal impact of tariffs on its operations and financial results
- Stryker, Boston Scientific down as new tariffs impact medtech industry